Drag a card by its title · ⚙ to size, swap or remove

The company

Ocular Therapeutix, Inc.

OCUL · Nasdaq

Health CareBiotechnologyNot moving yet

OCUL stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 28.9% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 4
Industry in uptrend: 18% -12 in 4 wk
Insider buys, 12 months: $923K
Insider sales, 12 months: $5.7M
Officials’ trades on record: 0
Institutions holding: 250 (-8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

22 Apr – 21 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months29

Buyers · sellers1 · 8

Who	Did	Shares	Traded
Todd AndermanChief Legal Officer	sold	11,984at $7.29	8 Oct 2026filed 13 Oct 2026
Jeffrey S. HeierChief Scientific Officer	sold	10,869at $7.05	2 Oct 2026filed 6 Oct 2026
Peter KaiserChief Development Officer	sold	9,990at $7.05	2 Oct 2026filed 6 Oct 2026
Donald NotmanChief Operating Officer	sold	1,099at $10.24	31 Aug 2026filed 2 Sep 2026
Pravin DugelDirector, Officer	sold	21,649at $10.77	24 Aug 2026filed 26 Aug 2026
Jeffrey S. HeierChief Scientific Officer	sold	3,296at $10.78	24 Aug 2026filed 26 Aug 2026
Sanjay NayakChief Strategy Officer	sold	1,897at $10.78	24 Aug 2026filed 26 Aug 2026
Peter KaiserChief Development Officer	sold	3,035at $10.77	24 Aug 2026filed 26 Aug 2026
Nadia WaheedChief Medical Officer	sold	14,828at $8.27	3 Jun 2026filed 5 Jun 2026
Sanjay NayakChief Strategy Officer	sold	1,858at $8.20	26 May 2026filed 28 May 2026
Jeffrey S. HeierChief Scientific Officer	sold	3,018at $8.20	26 May 2026filed 28 May 2026
Peter KaiserChief Development Officer	sold	2,967at $8.20	26 May 2026filed 28 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders250-8 on the quarter

New · exited33 · 41

Reported value$2.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	32,844,043$322.5M	+190,279+0.6%
Deep Track Capital, LPunchanged · filed 14 Aug 2026	19,686,282$193.3M	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	19,376,555$190.3M	+3,243,624+20.1%
Avoro Capital Advisors LLCadded · filed 14 Aug 2026	12,540,000$123.1M	+225,000+1.8%
Summer Road LLCadded · filed 10 Aug 2026	12,208,296$119.9M	+328,471+2.8%
Venrock Adviser, LLCunchanged · filed 14 Aug 2026	10,346,926$101.6M	00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	8,832,595$86.7M	+113,556+1.3%
Logos Global Management LPadded · filed 14 Aug 2026	5,300,000$52.0M	+1,450,000+37.7%
STATE STREET CORPadded · filed 7 Aug 2026	5,233,282$51.4M	+524,863+11.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	5,021,092$49.3M	+491,907+10.9%